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Abstract
Purpose Treatment options in Graves’ disease are clearly
deﬁned, but management practices and the perceptions of
success are varied. The outcomes of treatment in large
consecutive cohorts of Graves’ disease have not been well
characterised. The study describes the epidemiology, man-
agement strategies and medium term outcomes following
anti-thyroid drug treatment, radio-iodine ablation and sur-
gery in Graves’ disease.
Methods All patients (n= 659) who received treatment for
a new diagnosis of Graves’ disease in secondary care over a
5 year period were included with a median (interquartile
range) follow-up of 42.9 (29–57.5) months.
Results The age adjusted incidence of adult onset Graves’
disease in Shefﬁeld, UK was 24.8 per 100,000 per year.
Excluding 35 patients lost to follow-up, 93.1% (n= 581)
were controlled on anti-thyroid drug treatment. Of these,
73.6% went into remission following withdrawal of anti-
thyroid drugs; 5.2% were still undergoing initial therapy;
13.3% lost control whilst on anti-thyroid drugs; and 7.9%
went on to have either surgery or radio-iodine ablation
whilst controlled on anti-thyroid drugs. Of the 428 patients
who achieved remission, 36.7% relapsed.
Of 144 patients who had radio-iodine ablation treatment,
5.6% relapsed and needed further treatment. Of 119 patients
having surgery, 5.2% had long-term hypoparathyroidism
and none had documented long-term recurrent laryngeal
nerve palsy.
Conclusions In the follow-up, 39.9% of patients underwent
surgery or radio-iodine ablation with little morbidity. Up to
two-thirds of patients who achieved remission did not
relapse. Data on effectiveness and risks of treatments for
Graves’ disease presented in this study will help clinicians
and patients in decision making.
Keywords Graves’ disease ● Thyroid ● Hyperthyroidism ●
Anti-thyroid drugs ● Surgery ● Radio-iodine
Introduction
Graves’ disease is the commonest cause of hyperthyroidism,
typically presenting in patients between 40–60 years [1, 2].
Auto-antibodies, primarily Thyroid stimulating hormone
Receptor Antibody (TRAb), are the driving force behind the
disease but underlying mechanisms are still not completely
understood. Good epidemiological data on the disease is
lacking as epidemiological studies focus on ‘hyperthyroid-
ism’ in general and not speciﬁcally on Graves’ disease [3].
Clinical and biochemical features of thyrotoxicosis in
addition to an elevated TRAb, ophthalmopathy (and/or
dermopathy), or diffuse increase on radio-active iodine or
technetium uptake scan conﬁrm a diagnosis of Graves’ dis-
ease [4]. Radio-isotope scan helps to differentiate between
thyroiditis and other causes of hyperthyroidism [5]. Thyroid
ultrasound can give information on vascularity, presence of
thyroid nodules and size of the thyroid gland [6].
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The approach to investigation and treatment of Graves’
disease varies widely [7]. In general, patients are started on
thionamide medications to control thyroid hormone pro-
duction and release, thereby relieving symptoms. Methima-
zole or carbimazole (which is converted to methimazole in
the blood stream) is invariably used as ﬁrst-line treatment.
Due to the risk of hepatotoxicity, propylthiouracil is usually
reserved for those who are intolerant to carbimazole, women
in the ﬁrst trimester of pregnancy, or those in thyroid storm
[8–10]. The primary aim of anti-thyroid drug (ATD) treat-
ment is to achieve normalisation of thyroid hormone pro-
duction and induce remission of disease; occasionally it may
be to prepare patients for radio-iodine ablation (RIA) or
surgery [10]. One of two strategies is used—titration of dose
to biochemical response, or block and replace treatment (i.e.,
ﬁxed high dose ATDs given in combination with thyroid
hormone replacement) [11]. A course of ATD treatment
usually lasts for between 6–18 months as treatment beyond
this has not been shown to have any additional beneﬁts [11].
Some patients continue with low dose ATDs in the long
term. This approach is also used in relapsed Graves’ disease
as an alternative to RIA or thyroidectomy [12].
Relapse following ATD treatment is between 30–40% in
the ﬁrst 12 months and approximately 50–60% in long term
[13, 14]. Following failure of medical therapy, deﬁnitive
treatment with either surgery or RIA is considered. RIA is
more popular in North America and is often used as a ﬁrst-
line therapy for Graves’ disease. However it is not suitable for
pregnant patients and those with severe eye disease. Alter-
natively, thyroidectomy is effective in inducing remission, has
a negligible relapse rate and is particularly useful in patients
unsuitable for RIA and those with large goitres [1]. However
there is potential for complications such as recurrent laryngeal
nerve (RLN) damage and hypoparathyroidism. In the UK,
there is signiﬁcant variation in choice of deﬁnitive manage-
ment for Graves’ disease. Worryingly, clinicians’ perceptions
on the risks and beneﬁts of each option vary widely [15].
Good quality data information on short and long-term
outcomes of treatment in consecutive cohorts of patients
with Graves’ disease is lacking. To our knowledge, there is
no study describing natural history following initial diag-
nosis and outcomes from ATD, surgery and radio-iodine in
a single cohort of patients. The aim of this study is to
explore the epidemiology, clinical features and short to
medium-term outcomes following management of Graves’
disease in a consecutive cohort of newly diagnosed patients
managed in secondary care in the UK.
Methods
This is a retrospective cohort study of patients treated for a
new diagnosis of Graves’ disease at Shefﬁeld Teaching
Hospitals (STH) over a 5 year period (July 2008 to June
2013). Patients were identiﬁed by exploring a database
(ERUS) of correspondence in the endocrine unit. Patients
diagnosed during pregnancy and Graves’ disease or diffuse
thyrotoxicosis secondary to drugs such as alemtuzumab and
amiodarone are likely to be included in this cohort. Data on
these patients such as demographics (age, gender and
postcode), presentation, biochemical features (TSH -
Thyroid Stimulating Hormone, FT4 - Free Thyroxine, FT3 -
Free Tri-iodothyronine, TRAb - TSH Receptor Antibody
and TPO - Thyroid Peroxidase), treatment, outcomes and
status of disease when last available was collected from
electronic records. Data on smoking was not available.
The reference ranges for normal values for the various
laboratory investigations include 0–34 IU/ml for TPO,
0.27–4.2 mIU/L for TSH, 12–22 pmol/L for FT4 and
3.1–6.8 pmol/L for FT3. Results for TRAb are presented as
either positive (>1.5 IU/L), indeterminate (1–1.5 IU/L) or
negative (0–0.9 IU/L). The BRAHMS TRAK human LIA
method was used for the TRAb assay. For patients where
multiple results prior to treatment were available, the ﬁrst
available thyroid proﬁle and auto-antibody results prior to
starting medical therapy have been used for analysis. Where
a date of starting medical therapy was not available, it was
substituted by the date of diagnosis.
The outcome of initial medical treatment was determined
from biochemical response (FT4 and TSH) and clinician’s
interpretation of the biochemistry and recorded as follows:
● Controlled disease—normalisation of biochemistry
whilst on ATDs or within 1 month of withdrawal of
ATDs
● Disease remission—patients whose disease was con-
trolled with ATDs and where control was maintained for
at least a month after withdrawal of medical treatment
● Uncontrolled disease—persistently abnormal biochem-
istry despite ATDs or intolerant to ATDs
● Unknown—where data on response was not available
Patients that relapsed after initial remission with ATDs
were started on ATDs again either as a further course of
treatment or as a bridge to deﬁnitive treatment with surgery
or RIA. In patients undergoing RIA therapy, goitre size was
estimated by palpation and technetium scan to determine
dose of radio-active iodine. In general, RIA therapy was
avoided in patients with eye disease. However, when used
in accordance to patient preference, prednisolone was star-
ted 2–3 days prior to treatment and gradually reduced over
3 weeks after treatment. RIA therapy and follow-up was
provided as an outpatient treatment. In patients undergoing
surgery, total-thyroidectomy or near-total thyroidectomy
(TT) was performed. Pre-operative laryngoscopy, anaes-
thetic assessment and biochemical testing to ensure ade-
quate control of thyroid levels were regularly performed.
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Lugol’s iodine (0.3 ml TDS for 10 days pre-operatively)
was routinely used to reduce gland vascularity. Patients
with inadequate control of hyperthyroidism were admitted
for monitored in-patient treatment for 7–10 days prior to
surgery. Treatment included a combination of ATD, Lugol’s
iodine, beta-blockers and cholestyramine. Patients were
typically discharged 1 day after surgery after initiation of
thyroxine. Calcium levels were monitored after surgery and
post-operative laryngoscopy was performed selectively in
the initial part of the study (if patients had voice or swal-
lowing problems) and routinely in the latter part of the study
(as practice had changed following guidelines from the
British Association of Endocrine and Thyroid Surgeons).
Patients were followed up for a median (IQR - interquartile
range) time of 42.9 (29.0–57.5) months after the date of
diagnosis. The date when information was last collected was
July 2015.
All data was recorded on an Excel spreadsheet. A number
of key variables were validated by an independent second
observer. Data analysis was primarily performed using the
IBM SPSS statistics version 21 software package; however,
some calculations including incidence rates were done on
Microsoft Excel 2007. For calculation of incidence rates,
only patients from within the catchment area for STH were
used. Population data was taken from the April 2011 census
to calculate a crude incidence rate for adult Graves’ disease
[16]. The number of people in Shefﬁeld stratiﬁed by age and
gender were obtained and the male to female ratio for the
adult population was extrapolated from the ratio in the
overall population. This was used to calculate age and gender
adjusted incidence rates for each of the included 21 areas
identiﬁed by the ﬁrst part of the postcode. As some of the ‘S’
postcodes were in catchment areas for other nearby hospitals,
all areas where the age and gender adjusted incidence rates
were below 0.050 per thousand per year were excluded. This
threshold was the level at which all relevant (i.e., STH)
catchment areas were captured in the incidence calculations.
The Pearson χ2 test with continuity correction or Fisher’s
exact test was used to determine associations and differences
in categorical data sets. The Mann–Whitney U test was used
for comparisons of continuous data. A signiﬁcance value of
P< 0.05 was used in all cases. The Kaplan–Meier method
was used to produce a survival curve comparing relapse rates
between patients who had block and replace therapy and
those who had titration therapy. To determine the inﬂuence
of factors on the outcome of medical treatment, a binary
logistic regression analyses was performed on variables
shown to be signiﬁcant on univariable analyses.
The project was approved as a service evaluation study
by the clinical effectiveness unit in STH (Ref. 41213) and
given the observational nature of the study, approval from
the regional ethics committee or individual patient consent
was not deemed necessary.
Results
Six hundred and ﬁfty-nine patients treated for a new
diagnosis of Graves’ disease over 5 years were included.
The median (IQR) age at diagnosis was 44 (33–56) years.
The cohort included one ‘paediatric’ patient who was
diagnosed at the age of 16. Females accounted for 79.8% (n
= 526) of patients, giving a crude ratio of 4:1 (female to
male). The adjusted sex ratio was 3.9:1 when standardised
to the gender distribution in the local population (1.03:1).
93.8% (n= 618) were electively referred from primary care
and 6.2% (n= 41) presented to accident and emergency
services.
Of the 658 adult patients identiﬁed, 644 lived in the
Shefﬁeld area (denoted by an ‘S’ postcode). After exclusion
of patients in ‘S’ postcodes that were in catchment areas for
other hospitals, 609 patients were included in incidence
calculations. The adult population in the relevant postcodes
was 490,555; as per the 2011 census. The overall crude
incidence of Graves’ disease was 24.8 per 100,000 popu-
lation per year. The age and gender adjusted incidence rates
of adult Graves’ disease presenting to hospital are 24.9 and
24.8 per 100,000 per year, respectively (Fig. 1). Gender
speciﬁc incidence of adult Graves’ disease was 11.0 and
37.9 per 100,000 population per year for males and females
respectively.
Presentation and diagnosis
Of 372 patients where TRAb antibody results prior to
initiation of medical therapy were available, 5.9% (n= 22)
of patients had a negative TRAb, 2.4% (n= 9) were inde-
terminate and 91.7% (n= 341) were positive. A detailed
comparison between TRAb positive and ‘indeterminate or
negative’ groups is given in Table 1. TPO antibody levels
prior to initiation of medical therapy were available in 323
patients. It was positive ( ≥ 35 IU/L) in 73.1% (n= 236) and
negative (<35 IU/L) in 26.9% (n= 87).
All patients except one had a suppressed TSH prior to
treatment initiation. One patient with TSH in normal range
had clinical features of hyperthyroidism, raised FT3 and
FT4 levels, positive TRAb, strong family history of thyroid
disease and a medical history of autoimmune disease. It was
felt that despite normal TSH levels, this patient would
beneﬁt from therapy. The median (IQR) FT4 and FT3 levels
prior to treatment were 33.0 (24.6–47.0) pmol/L and 12.9
(8.8–20.4) pmol/L, respectively.
Technetium (99mTc) uptake scan was performed in only
26.7% (n= 176) of patients. In 81.8% (n= 144) of these
patients it was performed in preparation for RIA therapy.
Ultrasound scan was recorded in 67 patients and in 19 of
these prior to treatment initiation.
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Management
Primary care physicians initiated ATD treatment in 38.9%
of patients (246/633), where data was available. Carbima-
zole was the preferred thionamide, used in 98.2% (n= 647).
Carbimazole was used alone in 88.0% (580/659) as opposed
to PTU in 1.8% (10/659). Both thionamides were used
sequentially in 10.2% (67/659) and in 2 patients carbima-
zole was started after methimazole or thiamazole, both of
which were started abroad. A block and replace regime was
used in 83.0% (n= 547) of patients. For patients where the
duration of treatment was available (n= 451), the median
(range) duration of treatment for the ‘block and replace’ and
‘titration’ regimes were 8 (3–36) and 16 (0–24) months,
respectively. The commonest starting dose of carbimazole
was 40 mg once daily, which was used in 71.9% (402/559)
of cases where starting dose was available.
Figure 2 summarises the ﬂow of patients through their
treatments and their outcomes.
Excluding patients lost to follow-up (n= 35), 93.1% (n
= 581) were controlled on initial ATD treatment. In patients
where control was not achieved (6.9%, n= 43), 14.0% (n
= 6) were continuing initial therapy at last follow-up,
41.9% (n= 18) underwent surgery and 44.2% (n= 19) had
RIA therapy. In the controlled group (n= 581);
● 7.9% (n= 46) had deﬁnitive management [surgery (n=
18) or RIA therapy (n= 27)] for a variety of reasons
including co-existing goitre, side effects to treatment,
severe disease and patient preference.
● 13.3% (n= 77) suffered a loss of control whilst on
ATDs and of these 44.2% (n= 34) had surgery, 36.4%
(n= 28) had RIA therapy and 19.5% (n= 15) had
further ATD therapy.
Fig. 1 Postcode map of Shefﬁeld (United Kingdom) with gender-adjusted and age-adjusted incidence rates for Graves’ disease. AA, age-adjusted
incidence; GA, gender-adjusted incidence. Each outlined area refers to a postcode area in the city of Shefﬁeld
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Table 1 Comparison of TRAb
positive and TRAb negative
patients with Graves’ disease
TRAb Positive (n= 341) TRAb Indeterminate or
Negative (n= 31)
P value
Median (IQR) age at diagnosis 46 (33–57) 43 (26–65) 0.99*
F:M ratio 3.8:1 6.8:1 0.357**
TPO positive 74.5% (n= 187) 50.0% (n= 12) 0.016**
Median FT4 (IQR) prior to
treatment (pmol/L)
32.8 (24.4–44.5) 28.0 (24.5–35.2) 0.02*
Median FT3 (IQR) prior to
treatment (pmol/L)
13.3 (8.9–19.5) 8.2 (6.9–11.4) <0.01*
Technetium scan done? 25.2% (n= 86) 12.9% (n= 4) 0.089**
Outcome of medical treatment 0.004**
Uncontrolled or loss of
control
64 (19.9%) 2 (6.5%)
Controlled or remission 169 (52.5%) 27 (87.1%)
Relapse 89 (27.6%) 2 (6.5%)
%needing RIA / surgery 39.6% 9.7% 0.522**
*Mann–Whitney U test
**χ2
Fig. 2 Flow chart depicting
management pathway for
patients with Graves’ disease
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● 5.2% (n= 30) were still controlled and on initial therapy
at last follow-up (this includes both those on long-term
ATDs and those in whom the goal was to achieve
remission).
● 73.7% (n= 428) of the controlled group were able
to achieve remission after withdrawal of ATD
therapy. Of those who achieved remission (n= 428),
36.7 % (n= 157) had relapsed at last follow-up.
A number of factors were evaluated for their potential to
predict failure of medical therapy (deﬁned as patients
uncontrolled on medical treatment, patients that lost
control while on treatment and patients that relapsed after
cessation of medical treatment) and therefore the need for
deﬁnitive treatment. Failure of medical therapy was
signiﬁcantly higher in the block and replace group vs. the
titration group (46.8 vs. 29.9%, respectively, p= 0.003,
χ2 test with continuity correction) and signiﬁcantly lower in
TRAb-negative compared to TRAb-positive patients
(12.9 vs. 47.5% respectively, p< 0.001, χ2 test with con-
tinuity correction). Similarly, patients who failed medical
therapy had signiﬁcantly higher FT4 and FT3 levels
before treatment (p< 0.001, Mann–Whitney U test). Age at
diagnosis (p= 0.113; Mann–Whitney U test), gender
(p= 0.856; χ2 with continuity correction) and TPO
levels (p= 0.654; χ2 test with continuity correction) did
not have a signiﬁcant impact on the risk of failure of
medical treatment. Binary logistic regression analyses
including signiﬁcant variables (TRAb status, FT4 and FT3
levels and type of treatment) showed that only FT3 levels
(p= 0.015) and TRAb (p= 0.005) status predicted failure
of treatment.
In the patients who had remission after initial ATD
treatment, six patients had less than six weeks of treatment
and may be considered to have gone in to ‘spontaneous’
remission. In this group TRAb was positive in 4, equivocal
in 1 and negative in 1. TPO was positive in 5 patients and
no result was available for the remaining patient. None of
these 6 patients relapsed. In the group who did not relapse
(n= 271), two patients had surgery—one for a co-existing
indeterminate thyroid nodule and the other for a prominent
goitre.
Figure 3 shows a survival curve demonstrating time to
relapse in patients that had remission after anti-thyroid drug
treatment. In the group that relapsed (n= 157), 28.0% (n=
44) had surgery, 44.6% (n= 70) had RIA therapy and
24.2% (n= 38) had a second round of ATDs. Of the
remaining 5 patients, one died shortly after relapse (of other
causes), one was lost to follow-up, two developed hypo-
thyroidism subsequently and one was considering deﬁnitive
management at last follow-up.
Table 2 compares demographic and clinical character-
istics of patients who had surgery and RIA as deﬁnitive
treatment for Graves’ disease. Surgery was performed more
often in female patients as compared to males. Age, FT3
and FT4 levels prior to treatment were also found to be
signiﬁcantly associated with the type of deﬁnitive man-
agement; surgery being favoured in younger patients and
those with more severe disease.
One hundred and fourty-four patients had RIA therapy
for Graves’ disease. The median (range) dose of activity for
radio-iodine treatment was 516MBq (374–934). The med-
ian (IQR) follow-up time after RIA treatment was 25.7
(12.0–47.1) months. Of the patients who had RIA therapy
and a minimum of 3 months follow-up (n= 135), relapse
was observed in 8 patients (5.9%); all occurring within
6 months of RIA therapy. Four of these went on to have
further RIA therapy and the remaining four were managed
with ATDs.
One hundred and nineteen patients had surgery. Of 115
patients where histology was available, 5 (4.4%) had
malignant histology; all these tumours were papillary sub-
type of differentiated thyroid cancer. Post-operative com-
plications studied included hypocalcaemia and RLN injury.
Calcium results were available in 97.5% (n= 116) of
patients. One patient had pre-operative hypocalcaemia and
was excluded. 68.1% (n= 79) had post-operative adjusted
calcium levels of over 2.1 mmol/L. 16.4% (n= 19) had
transient hypocalcaemia which resolved without treatment;
10.3% (n= 12) had hypocalcaemia needing treatment and
Fig. 3 Kaplan–Meier survival curve showing time to relapse in
patients who were considered to have remission after ATD treatment
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resolved in 6 months or less and 5.2% (n= 6) needed
treatment for hypocalcaemia lasting for over 6 months. Data
on post-operative laryngoscopy was available in 73 of the
119 patients. Of these, 94.5% (n= 69) were normal and
5.5% (n= 4) had a transient vocal cord palsy (lasting less
than 6 months). No patient had long-term vocal cord
palsy. If the group of patients in whom data on post-
operative laryngoscopy was not available (n= 46)
are assumed to have had no RLN injury, the percentage
of patients in whom there is no injury increases to 96.1% (n
= 98).
Discussion
This study is the ﬁrst to report on the incidence of Graves’
disease in a UK population and examine the outcomes of a
consecutive cohort of patients who have had ATDs, radio-
iodine and surgery.
The incidence of Graves’ disease was 24.8 cases per
100,000 with an adjusted female to male ratio of 3.9:1.
Studies have described incidence of thyroid disorders [17,
18] but studies speciﬁcally on Graves’ disease are rare [3].
In Sweden, the reported incidence of Graves’ disease
(2003–2005) was 21.4 per 100,000 per year with a F:M
ratio of 5.6:1 [19]. The ratio of 3.9:1 reported in this study is
however in keeping with other studies in Iceland and
Sweden that reported a gender ratio of 4:1 in hyperthyr-
oidism in general [3]. The true incidence of hyperthyroid-
ism may vary between populations and factors such as
iodine levels in drinking water are thought to have a sig-
niﬁcant impact [20]. However, comparisons between
populations are difﬁcult due to different inclusion criteria,
TRAb methods and diagnostic methods [17, 21].
TRAb had a 91.7% sensitivity for Graves’ disease in our
cohort; similar to previous literature where TRAb has been
negative in up to 10.0% [1, 21]. It has been argued that
TRAb negative patients may not have Graves’ disease; but
usually, a combination of clinical features, biochemistry,
antibody proﬁle and imaging are used to make the diagnosis
and this combination remains the gold standard [21]. UK
guidelines currently recommend that TRAb testing is not
required to determine the cause of hyperthyroidism, parti-
cularly if the clinical features are suggestive of Graves’
disease [22]. TPO antibody was positive in 73.1% of those
tested which is in keeping with a similar previous studies
[23, 24].
Technetium (99mTc) uptake scan is not routinely per-
formed and is used less frequently since the introduction of
more accurate TRAb assays [6]. It is performed in pre-
paration for RIA therapy to assess gland size and calculate
dose of radio-iodine for ablation. 81.8% of patients who had
a Technetium (99mTc) uptake scan had RIA therapy in this
cohort, suggesting that the scan was used primarily in
preparation for RIA treatment.
In this series, the rate of initial control with ATDs was
93.1%. The overall failure rate of ﬁrst-line treatment with
ATDs (those with uncontrolled, loss of control or relapsed
disease) was 60% (271/452) at last follow-up. This excludes
patients with unknown outcomes (n= 35), those with ongo-
ing therapy (n= 36) and those who had deﬁnitive manage-
ment despite control (n= 46). Other studies have estimated
similar failure rates of around 50–60% [13, 14, 25]. Reports
do not clearly distinguish between patients who fail treatment
early in the course and those who relapse after remission. In
this study, of those who went into remission and where data
on follow-up times were available, relapse occurred in 25 and
33% at 12 and 24 months, respectively.
Table 2 Comparison of demographic and clinical features of patients undergoing surgery and RIA therapy
RIA therapy (n= 144) Surgery (n= 116) P value
Median (IQR) age at diagnosis 50.5 (43.0–65.3) 43.5 (30.1–51.0) <0.001**
Females/males (incidence 3.9:1) 2.5:1 6.4:1 0.003*
Mean FT4 level at presentation 36.4 (26.1–49.3) 43.6 (31.9–54.3) 0.037**
Mean FT3 level at presentation 13.8 (9.7–20.8) 20.9 (13.6–28.2) <0.001**
Median (range) age at intervention 50.9 (18.7–83.2) 39.5 (19.0–66.5) <0.001**
Positive TPO status before treatment 79.3% (n= 58) 72.9% (n= 59) 0.404*
Positive TRAb status before
treatment
97.3% (n= 73) 98.5% (n= 65) 1.000*
Indications for deﬁnitive treatment Uncontrolled on ATD 13.2% (n= 19) Uncontrolled on ATD 15.5% (n= 18)
Loss of control on ATD—19.4% (n= 28) Loss of control on ATD—29.3% (n= 34)
Relapse—48.6% (n= 70) Relapse—37.9% (n= 44)
Others—18.8% (n= 27) Others—17.2% (n= 20)
*Pearson-χ2
**Mann–Whitney U Test
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Carbimazole was the preferred thionamide, used in
98.2% of patients. Block and replace regimes were used in
83% of patients and these patients failed medical therapy
more often than those who had titration regimes (46.8 vs.
29.9%, respectively). But, the superiority of one treatment
over the other remains unclear [26]. Nedrebø et al. [27]
showed no signiﬁcant difference in remission rates between
patients treated with block and replace vs. titrate after
24 months follow-up in a prospective cohort of 218
patients. Grebe et al. [28] showed similar ﬁndings using
higher doses of carbimazole for block and replace (100 mg)
although this group had signiﬁcantly more side effects. It
has been argued that titration regimes are favourable due to
reduced side effect proﬁle [29–31] and the independence of
remission rates from drug type and dose [31, 32]. A recent
observational study of 450 patients also found no evidence
to support the hypothesis that block and replace regimes
resulted in more stable thyroid function [24]. Our results
may be explained in part by the fact that regimes were of
varying lengths unlike in most prospective, comparative
studies. The titration group were treated on average for
twice the length of time compared to block and replace
group (16 vs. 8 months, respectively).
Identiﬁcation of predictors of relapse in Graves’ disease
would help tailor treatment to speciﬁc patient groups. Various
factors such as smoking status, TRAb levels before and after
treatment, low TSH, goitre size and more recently, stress
events, are suggested to be signiﬁcant [25, 27, 33–39]. We
found that age, gender and TPO status did not inﬂuence
failure, conﬁrming previous ﬁndings [27, 35, 36, 40]. We
found that patients with more severe disease (higher FT3 and
FT4) were signiﬁcantly more likely to fail medical treatment.
This is contrary to ﬁndings of Glinoer et al. [37], where both
total-T3 and free-T3 and T4 did not predict relapse. However,
they were treated with an initial block and replace followed by
titration regime which is different to our study. A signiﬁcant
number of patients in this study also continued to take exo-
genous thyroxine during the 12 month follow-up period.
Cappelli et al. found in a prospective study of 216 patients
that patients who did not relapse after ﬁrst round of ATDs had
a signiﬁcantly lower T4 than those that did relapse [38].
Our results indicate that patients that were TRAb positive
are signiﬁcantly more likely to fail medical treatment,
conﬁrming ﬁndings in other studies [33–35]. Quadbeck
et al. [40] demonstrated that TRAb was a predictive marker
for relapse in Graves’ disease, but was dependent on TSH
levels. Hoermann et al. also reported similar ﬁndings [36].
However, Scott et al. [33] concluded that at high levels,
TRAb alone was an independent predictor of relapse.
We found that surgery was, signiﬁcantly, more com-
monly performed in younger, female patients with more
severe disease at presentation (higher FT3 and FT4). This
may be because some exclusion criteria for RIA (such as
pregnancy and breast feeding) apply exclusively to females.
It is also expected that younger patients will be more suitable
for surgery with fewer co-morbidities. TPO and TRAb
status at presentation did not predict choice of deﬁnitive
treatment.
In patients with a minimum of 3 months follow-up post-RIA
therapy (n= 135), relapse rate was 5.9%; all occurring within
6 months. This is in keeping with previous studies which have
reported success of RIA therapy to be over 85% [41, 42].
In surgical patients, 5.5% had temporary RLN damage;
transient and long term post-operative hypocalcaemia
occurred in 31.9 and 5.2%, respectively; and incidental
papillary thyroid cancer rate was 4.4%. The complication
rates were higher than those reported in a prospective study
in Poland (transient rate of 25%, long-term rate of 0%) on
including 96 patients who underwent total thyroidectomy
[43] However, the deﬁnitions of transient and long-term
hypoparathyroidism differ greatly between centres and this
can signiﬁcantly inﬂuence rates [44]. There is a wide range
(5.4–19%) in the rates of incidental thyroid cancer following
thyroidectomy reported in the literature [43, 45–47]. This
variation may be due to differences in the underlying cohorts,
the approach to diagnosis and the criteria for considering
surgical treatment; especially in patients with thyroid nodules
where the incidence of thyroid cancer has been reported to be
much higher [45, 47]. Stahopoulos et al. [48] similarly found
long-term hypoparathyroidism to be 5.4% post-operatively
with no patients having permanent RLN damage. A recent
study from our unit [49] on post-thyroidectomy hypo-
calcaemia reported transient and long-term rates of 29.0 and
5.5% in patients undergoing total thyroidectomy (for all
indications) over a 3.5 year period. No patients had recur-
rence of hyperthyroidism following surgery, consistent with
other recent literature [48, 50]. In conclusion, surgery is an
effective and safe management option for Graves’ disease.
Currently there is no consensus on the optimal man-
agement strategy after failure of ATDs. The choice between
RIA, thyroidectomy and a second round of ATDs appears to
be inﬂuenced by physician, patient, institutional and geo-
graphical preferences. There may be some reluctance
amongst clinicians to recommend thyroidectomy unless
RIA and ATDs are contraindicated but preference for
thyroidectomy appears to be increasing [48, 51, 52]. An
analysis by Haejin et al. [53] found that total thyroidectomy
was the most cost-effective strategy following failure of
ﬁrst-line ATDs for the model Graves’ patient in the US. The
choice of deﬁnitive management should be made on a case-
by-case basis and our results will aid clinicians in choosing
the best deﬁnitive treatment strategy for their patients fol-
lowing failure of ATDs.
This study is limited by its retrospective nature and the
lack of a complete dataset. Incidence rates may have been
under estimated as only patients presenting to secondary
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care were included. However, current practice in the UK is
for all patients with hyperthyroidism to be referred to sec-
ondary care by their general practitioner. The comparisons
between surgery and radio-iodine groups are subject to
selection bias. Although the choice of treatment was based
on recognised principles of management, the use of differ-
ent treatments were subject to the treating clinician’s dis-
cretion and patient choice; resulting in signiﬁcant
heterogeneity. Data on the rationale for the use of various
treatments was not recorded and detailed analyses of
patients undergoing a second round of ATDs was not per-
formed due to logistic difﬁculties and data availability.
However, the data provides signiﬁcant insight into practice
in secondary care in a large UK hospital and a pragmatic
understanding of the outcomes of treatment in real life.
In summary, this study has described the epidemiology
of Graves’s disease in a western population. The short to
medium-term outcomes following the management strate-
gies employed will help clinicians and patients in decision
making. Surgery and radio-iodine are both effective and
associated with minimal morbidity but controlled trials are
needed to evaluate their relative effectiveness in comparison
to each other and to further treatment with ATDs.
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